Hypocretin-1/ Orexin-A fragment1-16 as a potential surrogate marker for diagnosing narcolepsy type 1
Clicks: 1
ID: 313511
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #184 of 189 articles by views in Sleep & breathing = Schlaf & Atmung
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 189 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
STUDY OBJECTIVES: Loss of cerebrospinal fluid hypocretin-1/orexin-A (Hcrt-1) immunoreactivity is a biomarker for narcolepsy type 1 (NT1). The current radioimmunoassay (RIA) does not allow precise quantification, limiting the assessment of disease severity and evolution. This study aimed to reproduce previously proposed workflows to quantify Hcrt-1 and Hcrt-2 by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), identify RIA antibody targets, and to compare two purification methods in their ability to identify patients with NT1. METHODS: Solid phase extraction (SPE) and LC-MS/MS measurements of Hcrt-1 and -2 levels from 10 NT1 patients and 21 controls were implemented based on existing literature. Immunoprecipitation (IP) with magnetic beads coupled to the RIA antibody (Phoenix) was performed and peptides identified by MS. Finally, Hcrt-1 (full-length) and Hcrt-1 fragment1-16 levels were analyzed in 4 patients and 4 controls prepared from both workflows by nano-LC coupled to high-resolution mass spectrometry (nLC-HRMS). RESULTS: Despite linear calibration curves for Hcrt-1 and Hcrt-2 (R2 > 0.99) could be assessed with LC-MS/MS, full-length Hcrt-1 concentrations were at the low end of the calibration curve with slightly lower levels in NT1 (p = 0.04). Hcrt-2 was undetectable. The discovery experiment with IP most reliably identified Hcrt-1 fragment1-16. SPE revealed much higher concentrations than IP. Hcrt-11-16-levels allowed distinguishing patients and controls after SPE and IP, whereas full-length Hcrt-1-levels after IP did not. CONCLUSIONS: Hcrt-11-16 appears stable and abundant in CSF of controls, allows identification of patients with NT1 and is a promising surrogate marker. SPE seems more suitable for further method validation in clinical routine.
| Reference Key |
openalex_W7161288149
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Elena Wenz, Jean‐Christophe Prost, Sophie Braga-Lagache, Gabriela M Mäder, Jan D. Warncke, Martin Luginbühl, Patrick Y Wuethrich, Friedrich Lersch, Christoph Schankin, Irina Filchenko, Livia Fregolente, Kseniia Zub, Seiji Nishino, C R Largiader, Manfred Heller, Mehdi Tafti, Markus H Schmidt, Claudio L A Bassetti |
| Journal | Sleep & breathing = Schlaf & Atmung |
| Year | 2026 |
| DOI |
10.1093/sleep/zsag115
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.